Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 5
2011 5
2012 3
2013 2
2014 8
2015 10
2016 10
2017 8
2018 7
2019 4
2020 6
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial.
Hayes S, Obermair A, Mileshkin L, Davis A, Gordon LG, Eakin E, Janda M, Beesley VL, Barnes EH, Spence RR, Sandler C, Jones T, Vagenas D, Webb P, Andrews J, Brand A, Lee YC, Friedlander M, Pumpa K, O'Neille H, Williams M; ECHO Collaborative; Stockler M; ECHO trial. Hayes S, et al. Among authors: beesley vl. BMJ Open. 2023 Apr 13;13(4):e067925. doi: 10.1136/bmjopen-2022-067925. BMJ Open. 2023. PMID: 37055210 Free PMC article. Clinical Trial.
Patient age and risk of recurrence of primary melanoma at high risk of spread.
Ghiasvand R, Khosrotehrani K, Hughes MCB, von Schuckmann LA, Beesley VL, Malt M, Smithers BM, Green AC. Ghiasvand R, et al. Among authors: beesley vl. Br J Dermatol. 2021 Mar;184(3):566-568. doi: 10.1111/bjd.19601. Epub 2020 Nov 29. Br J Dermatol. 2021. PMID: 33053218 No abstract available.
Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor.
von Schuckmann LA, Hughes MCB, Ghiasvand R, Malt M, van der Pols JC, Beesley VL, Khosrotehrani K, Smithers BM, Green AC. von Schuckmann LA, et al. Among authors: beesley vl. JAMA Dermatol. 2019 Jun 1;155(6):688-693. doi: 10.1001/jamadermatol.2019.0440. JAMA Dermatol. 2019. PMID: 31042258 Free PMC article.
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Beesley VL, Ross TL, King MT, Campbell R, Nagle CM, Obermair A, Grant P, DeFazio A, Webb PM, Friedlander ML; OPAL Study Group. Beesley VL, et al. Gynecol Oncol. 2022 Feb;164(2):437-445. doi: 10.1016/j.ygyno.2021.12.006. Epub 2021 Dec 24. Gynecol Oncol. 2022. PMID: 34955238 Free article.
61 results